Reminder to register 📆➡️ Join us for our investor webcast featuring Matthew Wicklund, M.D., FAAN of @UTHealthSA & LGMD2I/R9 exec team who will discuss LGMD2I/R9 and review BBP-418 progress.

We’re excited to join @TheEndoSociety at #ENDO2025 to share updates from our ADH1 program, including 42-month Phase 2b results from encaleret treatment, pediatric baseline characteristics from CLARIFY, our disease monitoring study, insights from our genetic testing program, &

Heading to PHARMACHON in SF on July 12? Join us alongside @thechandlerproj to learn about the latest in research developments.

Register 📆➡️ Don’t miss our LGMD2I/R9 investor webinar on Friday, July 11 at 8:00 AM ET with Matthew Wicklund, M.D., FAAN of @UTHealthSA.

💚👉 We’re inspired by the powerful patient and caregiver voices elevated by @CureLGMD2i. One example of this is Jennifer and Ryan’s story, which shows the true resilience of how families navigate a rare disease diagnosis like LGMD2I/R9.

Today, we announced the closure of a European royalty financing for our near-complete stabilizer in transthyretin amyloid cardiomyopathy of $300 million with HealthCare Royalty and @BlueOwlCapital. Learn more:

Incredible to connect with families & clinicians, hear from LGMD advocates, and see real momentum in research & trial updates at this year’s Iowa Wellstone Dystroglycanopathy Patient & Family Conference. We are grateful to stand alongside this community, and we appreciate being a

Learn more and register ➡️ Join us for an investor webinar on Friday, July 11 at 8:00 AM ET with Matthew Wicklund, M.D., FAAN of @UTHealthSA, where he will share an overview on limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).

❤️➡️ New publication in @JCVPOnline highlighting more data for acoramidis as a near-complete TTR stabilizer.

Our medical affairs team recently attended the Annual Meeting of the American Association of Heart Failure Nurses (@AAHFN), where we had the privilege of connecting with dedicated heart failure professionals and engaging in meaningful scientific discussions. We're grateful for

Sun-Gou Ji, Ph.D., VP and Head of Computational Genetics, will be speaking at the Festival of Genomics Boston!. He’ll explore how real-world genomic data can uncover the true prevalence of rare diseases and why that is important when thinking about putting patients first. Catch

Over the past few weeks, the BridgeBio team joined four incredible advocacy conferences across Europe with @AISACOnlus, @BKMF, @assoappt, and @ANDO_Portugal. We’re so grateful for the opportunity to hear from the community and apply our learnings to our work.

Proud moment: BBOT, formerly a BridgeBio affiliate, is published in @Science Magazine !. BBO-10203 is designed to block the RAS-PI3Kα interaction stopping tumor growth without inducing hyperglycemia. A new chapter in precision oncology begins. Article:

This Father’s Day, we celebrate the courage, commitment, and strength of fathers everywhere, especially those living with or caring for loved ones with genetic conditions. To all the fathers making a difference today and every day, we see you, and we thank you.

Tune in here: 👉 We are proud that our CEO & Founder Neil Kumar, PhD, spoke at the @GoldmanSachs 46th Global Healthcare Conference 2025, where he shared updates on our #pipeline & our mission to put patients first by treating #geneticdiseases at their

MyAchonJourney is a community-informed resource developed to support families and provide a positive outlook on living life confidently with achondroplasia. Created in close collaboration with patient advocacy leaders and healthcare experts in skeletal dysplasia, this

We’re proud to share that our Chief Regulatory Officer, Adora Ndu, Pharm.D., J.D. participated in a panel at #NORD Disease Scientific Symposium on how to deliver impactful science for rare diseases by incorporating the patient voice into research design. The Symposium was a great

Our management team will present at the @GoldmanSachs 46th Annual Global Healthcare Conference 2025. We’ll discuss #pipeline progress, R&D strategy, and our approach to targeting #geneticdiseases at their source. 🔗 Investor webcast:

🎧 Hear how we’re building a new type of biotech company: In the past, many biotech companies overlooked rare diseases. In a One of One podcast with @TheTriumGroup, our CEO and founder, Neil Kumar shared how he built BridgeBio to fix this problem and

Caring for an infant or toddler with #achondroplasia may involve adaptations to support safety, comfort, and independence. Explore practical ideas for home and daycare on MyAchonJourney—along with more resources from the skeletal dysplasia community.